Supporting data for "Hybrid extracellular vesicles derived from γδ-T and cancer cells enhance homologous tumor targeting and antitumor immunity"

Despite various cancer therapies aiming to precise tumor targeting and enhanced control efficacy, off-target effects and inadequate cytotoxicity continue to pose significant challenges. Thus, many research focus on the engineering of tumor cell-derived exosomes (T-EVs) because of their intrinsic "homing" capacity to target tumor sites. Our group's prior research has emphasized the remarkable anti tumor properties of exosomes produced from γδ-T cells (γδ-T-EVs). This study aims to improve the targeting efficiency of exosomes (EVs) by creating hybrid exosomes (H-EVs) through a freeze-thaw method that merges γδ-T-EVs with T-EVs. These H-EVs possess the characteristics of EVs from both parent cell types, allowing them to specifically recognize and effectively eradicate the parent tumor cells. Moreover, the maturation of dendritic cells (DCs) and activation of T cells were observed following stimulation with H-EVs, contributing to the reversal of their suppression in the tumor microenvironment. Proteomic analysis revealed that integrins facilitate the "homing" capability of H-EVs to tumor sites. These H-EVs efficiently targeted tumors, eliminated tumors, and extended survival in mice models, indicating a promising therapeutic strategy for cancer. Nonetheless, additional research is required to translate this H-EVs technology into clinical trials.